REFERENCES
1. Hu C. Grants supporting research in China. Eur Heart J
2018;39:2342-4.
2. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively
inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res 2020;30:269-71.
3. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir
for Patients with Severe Covid-19. N Engl J Med 2020;382:2327-36.
4. Kalil AC, Patterson TF, Mehta AK, et al. ACTT-2 Study Group Members.
Baricitinib plus
Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med
2021;384:795-807.
5. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al.
Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med
2021;384:693-704.
6. Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs
through large-scale compound repurposing. Nature 2020;586:113-9.
7. Couzin-Frankel J.
Antiviral pills could
change pandemic’s course. Science 2021;374:799-800.
8. Ledford H.
COVID antiviral pills:
what scientists still want to know. Nature 2021;599:358-9.
9. Li R, Hou Y, Huang J, et al. Lianhuaqingwen exerts anti-viral and
anti-inflammatory activity against novel coronavirus (SARS-CoV-2).
Pharmacol Res 2020;156:104761.
10. Long QX, Liu BZ, Deng HJ, et al. Antibody Responses to SARS-CoV-2 in
Patients With COVID-19. Nat Med 2020;26:845-8.
11. Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to
the N-terminal domain of the Spike protein of SARS-CoV-2. Science
2020;369:650-5.
12. Ortigoza MB, Yoon H, Goldfeld KS, et al.
Efficacy and Safety
of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized
Clinical Trial. JAMA Intern Med 2022;182:115-26.
13. Park H, Tarpey T, Liu M, et al.
Development and
Validation of a Treatment Benefit Index to Identify Hospitalized
Patients With COVID-19 Who May Benefit From Convalescent Plasma.
JAMA Netw Open 2022;5:e2147375.
14. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma
therapy in severe COVID-284 19 patients. Proc Natl Acad Sci U S A
2020;117:9490-6.
15. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell
Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
Unexposed Individuals. Cell 2020;181:1489-501.e15.
16. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection
protects against rechallenge in rhesus macaques. Science 2020;369:812-7.
17. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against
SARS-CoV-2 in rhesus macaques. Science 2020;369:806-11.
18. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and
immunogenicity of a recombinant adenovirus type-5 vectored COVID-19
vaccine: a dose-escalation, open-label, non-randomised, first-in-human
trial. Lancet 2020;395:1845-54.
19. Zhu FC, Guan XH, Li YH, et al. COVID-19 vaccine in healthy adults
aged 18 years or older: a randomized, double-blind, placebo-controlled,
phase 2 trial. Lancet 2020;396:479-88.
20. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine
candidate for SARS-CoV-2. Science 2020;369:77-81.
21. Dai L, Zheng T, Xu K, et al. A Universal Design of Betacoronavirus
Vaccines against COVID-19, MERS, and SARS. Cell 2020;182:722-33.e11.
22. Ma LY, Chen WW, Gao RL, et al. China cardiovascular diseases report
2018: an updated summary. J Geriatr Cardiol 2020;17:1-8.
23. Weckbach LT, Schweizer L, Kraechan A, et al. EMB Study Group.
Association of
Complement and MAPK Activation With SARS-CoV-2-Associated Myocardial
Inflammation. JAMA Cardiol 2022;7:286-97.
24. Aschman T, Schneider J, Greuel S, et al.
Association
Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients
Who Have Died. JAMA Neurol 2021;78:948-60.
25. Bois MC, Boire NA, Layman AJ, et al.
COVID-19-Associated
Nonocclusive Fibrin Microthrombi in the Heart. Circulation
2021;143:230-43.
26. Kawakami R, Sakamoto A, Kawai K, et al.
Pathological Evidence
for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the
Week. J Am Coll Cardiol 2021;77:314-25.
27. Talasaz AH, Sadeghipour P, Kakavand H, et al.
Recent Randomized
Trials of Antithrombotic Therapy for Patients
With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol
2021;77:1903-21.
28. Gorecka M, Thirunavukarasu S, Levelt E, Greenwood JP.
Multiple Etiologies to
Myocardial Injury in COVID-19. JACC Case Rep 2021;3:971-2.
29. Shaw KE, Cavalcante JL, Han BK, Gössl M.
Possible Association
Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings.
JACC Cardiovasc Imaging 2021;14:1856-61.
30. Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN,
Parker MA, Kim RJ.
Patients
With Acute Myocarditis Following mRNA COVID-19 Vaccination.
JAMA Cardiol 2021;6:1196-201.
31. Dionne A, Sperotto F, Chamberlain S, Baker AL, Powell AJ, Prakash A,
Castellanos DA, Saleeb SF, de Ferranti SD, Newburger JW, Friedman KG.
Association of
Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case
Series of Children. JAMA Cardiol 2021;6:1446-50.
32. Brito D, Meester S, Yanamala N, et al.
High Prevalence of
Pericardial Involvement in College Student Athletes Recovering
From COVID-19. JACC Cardiovasc Imaging 2021;14:541-55.
33. Mitrani RD, Goldberger JJ.
Cardiac Arrests During
the COVID-19 Pandemic: The Perfect Storm. JACC Clin Electrophysiol
2021;7:12-5.
34. Musikantow DR,
Turagam MK, Sartori S, et al. Atrial Fibrillation in Patients
Hospitalized With COVID-19: Incidence, Predictors, Outcomes, and
Comparison to Influenza. JACC Clin Electrophysiol 2021;7:1120-30.
35. Johansson M, Ståhlberg M, Runold M, et al.
Long-Haul Post-COVID-19
Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia
Syndrome: The Swedish Experience. JACC Case Rep 2021;3:573-80.
36. O’Connell TF, Bradley CJ, Abbas AE, et al.
Hydroxychloroquine/Azithromycin
Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
JACC Clin Electrophysiol 2021;7:16-25.
37. Leong DP, Eikelboom JW, Yusuf S.
The Indirect
Consequences of the Response to the COVID-19 Pandemic. J Am Coll
Cardiol 2021;77:186-8.
38. Wadhera RK, Shen C,
Gondi S, Chen S, Kazi DS, Yeh RW. Cardiovascular Deaths During
the COVID-19 Pandemic in the United States. J Am Coll Cardiol
2021;77:159-69.
39. Rappuoli R, De Gregorio E, Del Giudice G, et al.
Vaccinology in
the post-COVID-19 era. Proc Natl Acad Sci U S A 2021;118:e2020368118.
40. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular
system. Nat Rev Cardiol 2020;17:259-60.
41. Cheng X, Ma C, Han Y. Changes in the work mode of cardiologists
during the COVID-19 epidemic in Wuhan. Eur Heart J 2020;41:2729-30.
42. Bhatt AS, Jering KS, Vaduganathan M, et al.
Clinical Outcomes in
Patients With Heart Failure Hospitalized With COVID-19. JACC Heart Fail
2021;9:65-73.
43. Alvarez-Garcia J, Lee S, Gupta A, et al.
Prognostic Impact of
Prior Heart Failure in Patients Hospitalized With COVID-19. J Am Coll
Cardiol 2020;76:2334-48.
44. Fernández-Ruiz I. RAAS inhibitors do not increase the risk of
COVID-19. Nat Rev Cardiol 2020;17:383.
45. Lim GB. Myocardial injury in patients with COVID-19. Nat Rev Cardiol
2020;17:454.
46.
Wu
L, O’Kane AM, Peng
H, Bi
Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications:
From molecular mechanisms to pharmaceutical management. Biochem
Pharmacol 2020;178:114114.
47.
Sharma
T,
Padala
PR, Mehta
JL. Loneliness and social isolation: determinants of cardiovascular
outcomes: Implications in COVID-19 era. Curr Cardiol Rev 2021;
17:e051121190873.
48. Van Belle E, Manigold T, Piérache A, et al.
Myocardial Infarction
incidence during national lockdown in two French provinces unevenly
affected by COVID-19 outbreak: An observational study. Lancet Reg
Health Eur 2021;2:100030.
49. Sassone B, Virzì S, Bertini M, et al.
Impact of
the COVID-19 lockdown on the arrhythmic burden of patients with
implantable cardioverter-defibrillators. Pacing Clin Electrophysiol
2021;44:1033-8.
50. Chan DZ, Stewart RA, Kerr AJ, et al.
The impact of a
national COVID-19 lockdown on acute coronary syndrome hospitalisations
in New Zealand (ANZACS-QI55). Lancet Reg Health West Pac 2020;5:100056.
51. Mesnier J, Cottin Y, Coste P, et al.
Hospital admissions
for acute myocardial infarction before and after lockdown according to
regional prevalence of COVID-19 and patient profile in France: a
registry study. Lancet Public Health 2020;5:e536-42.
52. Bonnet G, Panagides V, Becker M, et al. MODIF registry
investigators. ST-segment elevation myocardial infarction: Management
and association with prognosis during the COVID-19 pandemic in France.
Arch Cardiovasc Dis 2021;114:340-51.
53. Zachariah G, Ramakrishnan S, Das MK, et al; CSI-AMI Study group.
Changing pattern of
admissions for acute myocardial infarction in India during
the COVID-19 pandemic. Indian Heart J 2021;73:413-23.
54. Holt A, Gislason GH, Schou M, et al.
New-onset atrial
fibrillation: incidence, characteristics, and related events following a
national COVID-19 lockdown of 5.6 million people. Eur Heart J
2020;41:3072-9.
55. Severino P, D’Amato A, Saglietto A, et al.
Reduction in heart
failure hospitalization rate during coronavirus disease 19 pandemic
outbreak. ESC Heart Fail 2020;7:4182-8.
56. Butt JH, Østergaard L, Gerds TA, et al.
The Association
between Cardiovascular Disease Admission Rates and
The Coronavirus Disease 2019 Lockdown and Reopening of a Nation: a
Danish Nationwide Cohort Study. Eur Heart J Qual Care Clin Outcomes
2021:qcab021.
57. Rangashamaiah S, Hayagreev V, Krishnan S, Prabhavathi B, Manjunath
CN. The impact of
COVID19 nationwide lock-down on STEMI hospitalization and outcomes in
South India. Indian Heart J 2021;73:379-81.
58. Bromage DI, Cannatà A, Rind IA, et al.
The impact
of COVID-19 on heart failure hospitalization and management: report from
a Heart Failure Unit in London during the peak of the pandemic. Eur J
Heart Fail 2020;22:978-84.
59. Jayagopal PB, Abdullakutty J, Sridhar L, et al.
Acute decompensated
heart failure (ADHF) during COVID-19 pandemic-insights from South
India. Indian Heart J 2021;73:464-9.
60. Dover AR, Ritchie SA, McKnight JA, et al.
Assessment of the
effect of the COVID-19 lockdown on glycaemic control in people with type
1 diabetes using flash glucose monitoring. Diabet Med 2021;38:e14374.
61. Szarfer JL, Puente L, Bono L, et al.
Impact of a
prolonged COVID-19 lockdown on patterns of admission, mortality and
performance indicators in a cardiovascular intensive care unit. Int J
Qual Health Care 2021;33:mzab029.
62. Campanile A, Verdecchia P, Ravera A, et al.
Intensive cardiac care
unit admission trends during the COVID-19 outbreak in Italy: a
multi-center study. Intern Emerg Med 2021:1-10.
63. Kostev K, Kumar S, Konrad M, Bohlken J.
Prescription rates
of cardiovascular and diabetes therapies prior to and during
the COVID-19 lockdown in Germany. Int J Clin Pharmacol Ther
2020;58:475-81.
64. Luedde M, Loosen S, Konrad M, Tanislav C, Roderburg C, Kostev K.
Increased pharmacy
purchases of cardiovascular drugs from wholesalers prior to the first
and second COVID-19 lockdowns. Int J Clin Pharmacol Ther 2021;59:572-7.
65. Kwok CS, Gale CP, Curzen N, et al.
Impact of
the COVID-19 Pandemic on Percutaneous Coronary Intervention in England:
Insights From the British Cardiovascular Intervention Society PCI
Database Cohort. Circ Cardiovasc Interv 2020;13:e009654.
66. Kwok CS, Gale CP, Kinnaird T, et al.
Impact of COVID-19 on
percutaneous coronary intervention for ST-elevation myocardial
infarction. Heart 2020;106:1805-11.
67. Kobo O, Efraim R, Saada M, et al.
The impact
of lockdown enforcement during the SARSCoV-2 pandemic on the timing of
presentation and early outcomes of patients with ST-elevation myocardial
infarction. PLoS One 2020;15:e0241149.
68. Nader J, Anselmi A, Tomasi J, et al.
Adult cardiac surgery
during COVID-19 lockdown: Impact on activity and outcomes in a
high-volume centre. Arch Cardiovasc Dis 2021;114:364-70.
69. Khalil KH, Sá MPBO, Vervoort D, et al.
Impact of
the COVID-19 pandemic on coronary artery bypass graft surgery in Brazil:
A nationwide perspective. J Card Surg 2021;36:3289-93.
70. Roman M, Harky A, Brazier A, et al.
Turn down
of acute aortic syndrome cases during COVID-19: Results from UK
multicentre studies. J Card Surg 2021;36:199-202.
71. Chalasani M, Nasir K, Gupta MD, Kalra A.
The Covid-19 pandemic
and India’s cardiovascular disease burden: Finding the right balance.
Indian J Med Ethics 2020;-(-):1-3.
72. Sacre JW, Holmes-Truscott E, Salim A, et al.
Impact of
the COVID-19 pandemic and lockdown restrictions on psychosocial and
behavioural outcomes among Australian adults with type 2 diabetes:
Findings from the PREDICT cohort study. Diabet Med 2021;38:e14611.
73. Li JW, Guo YT, Di Tanna GL, Neal B, Chen YD, Schutte AE.
Vital Signs During
the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants
in Wuhan and Four Nearby Capital Cities in China. Glob Heart
2021;16:47.
74. Aktaa S, Yadegarfar ME, Wu J, et al.
Quality
of acute myocardial infarction care in England and Wales during
the COVID-19 pandemic: linked nationwide cohort study. BMJ Qual Saf
2021;bmjqs-2021-013040.
75. Liu J, Zhang L, Yan Y, et al.
Excess mortality in
Wuhan city and other parts of China during the three months of
the covid-19 outbreak: findings from nationwide mortality registries.
BMJ 2021;372:n415.
76. Topriceanu CC, Wong A, Moon JC, et al.
Impact of lockdown on
key workers: findings from the COVID-19 survey in four UK national
longitudinal studies. J Epidemiol Community Health 2021;75:955-62.
77. Okely JA, Corley J, Welstead M, et al.
Change in Physical
Activity, Sleep Quality, and Psychosocial Variables
during COVID-19 Lockdown: Evidence from the Lothian Birth Cohort 1936.
Int J Environ Res Public Health 2020;18:210.
78. Cammalleri V, Muscoli S, Benedetto D, et al.
Who Has Seen Patients
With ST-Segment-Elevation Myocardial Infarction? First Results From
Italian Real-World Coronavirus Disease 2019. J Am Heart Assoc
2020;9:e017126.
79. Secco GG, Zocchi C, Parisi R, et al.
Decrease and Delay in
Hospitalization for Acute Coronary Syndromes During the
2020 SARS-CoV-2 Pandemic. Can J Cardiol 2020;36:1152-5.
80. Rieder M, Gauchel N, Kaier K, et al.
Pre-medication with
oral anticoagulants is associated with better outcomes in a large
multinational COVID-19 cohort with cardiovascular comorbidities. Clin
Res Cardiol 2021:1-11.
81. Du X, Shi L, Cao W, Zuo B, Zhou A.
Add-on effect of
Chinese herbal medicine in the treatment of mild to moderate COVID-19: A
systematic review and meta-analysis. PLoS One 2021;16:e0256429.
82. Kite TA, Ludman PF, Gale CP, et al; International COVID-ACS Registry
Investigators.
International
Prospective Registry of Acute Coronary Syndromes in Patients
With COVID-19. J Am Coll Cardiol. 2021;77(20):2466-76.
83. Garcia S, Dehghani P, Grines C, et al; Society for Cardiac
Angiography and Interventions, the Canadian Association of
Interventional Cardiology, and the American College of Cardiology
Interventional Council.
Initial Findings From
the North American COVID-19 Myocardial Infarction Registry. J Am Coll
Cardiol 2021;77:1994-2003.
84. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group
for Covid-19. China Medical Treatment Expert Group for Covid-19.
Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J
Med 2020;382:1708-20.
85. Lu YL, Zhu L, Hou GH, et al. Expert consensus on nursing management
for patients undergoing primary percutaneous coronary intervention
during the COVID-19 pandemic. Cardiol Plus 2020;5:81-8.
86. Hu CS. Analysis of COVID-19 Cases and Public Measures in China. SN
Compr Clin Med 2020;2:1306-12.
87. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With
Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA
Cardiol 2020;5:802-10.
88. Shi S, Qin M, Cai Y, et al. Characteristics and Clinical
Significance of Myocardial Injury in Patients With Severe Coronavirus
Disease 2019. Eur Heart J 2020;41:2070-9.
89. Chen Q, Xu L, Dai Y, et al. Cardiovascular manifestations in severe
and critical patients with COVID-19. Clin Cardiol 2020;43:796-802.
90. Xiang D, Xiang X, Zhang W, et al. Management and Outcomes of
Patients With STEMI During the COVID-19 Pandemic in China. J Am Coll
Cardiol 2020:76:1318-24.
91. Han Y, Zeng H, Jiang H, et al. CSC Expert Consensus on Principles of
Clinical Management of Patients with Severe Emergent Cardiovascular
Diseases during the COVID-19 Epidemic. Circulation 2020;141:e810-6.
92. Li H, Gu X, Li H, et al.
Risk factors
of viral RNAaemia and its association with clinical prognosis among
patients with severe COVID-19. Chest 2021;159:1382-6.
93. Stephenson KE, Le Gars M, Sadoff J, et al.
Immunogenicity of the
Ad26.COV2.S Vaccine for COVID-19. JAMA 2021;325:1535-44.
94. Turner JS, O’Halloran JA, Kalaidina E, et al.
SARS-CoV-2 mRNA vaccines induce
persistent human germinal centre responses. Nature 2021;596:109-13.
95. Bartsch YC, Tong X, Kang J, et al.
Omicron variant
Spike-specific antibody binding and Fc activity is preserved in
recipients of mRNA or inactivated COVID-19 vaccines. Sci Transl Med.
2022:eabn9243.
96. Cheng SMS, Mok CKP, Leung YWY, et al.
Neutralizing antibodies
against the SARS-CoV-2 Omicron variant BA.1 following homologous and
heterologous CoronaVac or BNT162b2 vaccination. Nat Med 2022;28:486-9.
97. Chen GL, Li XF, Dai XH, et al.
Safety and
immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a
randomised, double-blind, placebo-controlled, phase 1 trial. Lancet
Microbe 2022;3:e193-202.
98. Rauseo AM, O’Halloran JA.
What Are the Clinical
Implications of the SARS-CoV-2 Variants: 5 Things Every Cardiologist
Should Know. JACC Basic Transl Sci 2021;6:305-8.
99. Cui X, Wang P, Wei Z.
Emergency use
of COVID-19 vaccines recommended by the World Health Organization (WHO)
as of June 2021. Drug Discov Ther 2021;15:222-4.
100. Kotoulas AS, Karamanavis D, Lambrou GΙ, Karanikas P.
A pilot study of the
depression, anxiety and stress in Greek military personnel during the
first year of the COVID-19 pandemic. BMJ Mil Health
2021;bmjmilitary-2021-001874.
101. Hu CS, Tkebuchava T, Wu QH, Hu DY. C-type hypertension:an ignored
new killer? Cardiology Plus 2017;2:1-4.
102. Hu C, Tkebuchava T. Soccer Related Emotion and Stress-induced
Cardiovascular Events. Cardiology Plus 2018;3:66-70.
103. García-Fiñana M, Hughes DM, Cheyne CP, et al.
Performance of the
Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool
asymptomatic testing pilot: population based cohort study. BMJ
2021;374:n1637.
104. Hu C, Tkebuchava T. Visual and measured clinical phenotypes:
Potential targets for cardiovascular prevention. Cardiology Plus
2019;4:43-6.
105. Gu RP, Li T, Zheng LP.
Psychological
safeguards for Chinese People’s Liberation Army fighting COVID-19. BMJ
Mil Health 2020;166:443.
106. Parsons IT, Gifford RM, Stacey MJ, Lamb LE, O’Shea MK, Woods DR.
Does vitamin D
supplementation prevent SARS-CoV-2 infection in military personnel?
Review of the evidence. BMJ Mil Health 2021;167:280-6.
107. Greenberg N, Cooke J, Sullivan E, Tracy DK.
Mental health plan for
workers of the London Nightingale Hospital: following the evidence to
support staff. BMJ Mil Health 2021;167:107-9.
108. Lamontagne F, Agoritsas T, Siemieniuk R, et al.
A living WHO guideline
on drugs to prevent covid-19. BMJ 2021;372:n526.
109. Arena R, Bond S, Calvo IR, et al. HL-PIVOT Network.
Shelter from the
cytokine storm: Healthy living is a vital preventative strategy in
the COVID-19 era. Prog Cardiovasc Dis 2021;S0033-0620(21)00066-9.
110. Xie Y, Xu E, Bowe B,
Al-Aly
Z. Long-term cardiovascular outcomes of COVID-19. Nat
Med 2022;28:583-90.
111. Gupta S, Mitra A.
Challenge
of post-COVID era: management of cardiovascular complications in
asymptomatic carriers of SARS-CoV-2. Heart Fail Rev 2022;27:239-49.
112. Sigfrid L, Cevik M, Jesudason E, et al.
What is the recovery
rate and risk of long-term consequences following a diagnosis
of COVID-19? A harmonised, global longitudinal observational study
protocol. BMJ Open 2021;11:e043887.
113. Nakayama A, Takayama N, Kobayashi M, et al.
Remote cardiac
rehabilitation is a good alternative of outpatient cardiac
rehabilitation in the COVID-19 era. Environ Health Prev Med 2020;25:48.
114. Żak MM, Stock A, Stadlbauer D, et al.
Development and
characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike
antibodies. Heliyon 2021;7:e08444.
115. Ciampi Q, Antonini-Canterin F, Barbieri A, et al. SIECoVId Study
Group On Behalf Of The Italian Society Of Echocardiography And
Cardiovascular Imaging Siecvi.
Reshaping of Italian
Echocardiographic Laboratories Activities during the Second Wave
of COVID-19 Pandemic and Expectations for the Post-Pandemic Era. J Clin
Med 2021;10:3466.
116. Kaushik A, Patel S, Dubey K.
Digital cardiovascular care
in COVID-19 pandemic: A potential alternative? J Card Surg
2020;35:3545-50.
117. Suri JS, Agarwal S, Gupta SK, et al.
A narrative review on
characterization
of acute respiratory distress syndrome in COVID-19-infected lungs using
artificial intelligence. Comput Biol Med 2021;130:104210.
118. Hikisz P, Bernasinska-Slomczewska J.
Beneficial Properties
of Bromelain. Nutrients 2021;13:4313.
119. Rao G, Singh A, Gandhotra P, et al.
Paradigm Shifts in
Cardiac Care: Lessons Learned From COVID-19 at a Large New York
Health System. Curr Probl Cardiol 2021;46:100675.
120. Hu C. Combat COVID-19 with “ISISI” Strategies for Human
Cardiocerebrovascular Health. Manuscript in Submission & Under Review.
2022.